REG - RTW Biotech Opp. - Monthly Valuation Update and Factsheet

RTW Biotech OpportunitiesAnnouncement

15/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240715:nRSO3166Wa&default-theme=true

RNS Number : 3166W  RTW Biotech Opportunities Ltd  15 July 2024

LEI: 549300Q7EXQQH6KF7Z84

15 July 2024

RTW Biotech Opportunities Ltd

Monthly Valuation Update and Factsheet

+7.7% NAV movement for the month

RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited net
asset value attributable to the ordinary shares of the Company at the close of
business on 30 June 2024 (the "NAV") was US$655.4 million, or US$1.95 per
ordinary share, +7.7% from the previous month.

The monthly factsheet is available on the Company's website:

 

https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/)

 

Highlights from the Manager's quarterly letter:

·     NAV per share returned +0.2% in the second quarter. The Russell 2000
Biotech Index and the Nasdaq Biotech Index returned -6.51% and +2.6%
respectively in the second quarter. Year to date, the Russell 2000 Biotech
Index has returned +1.68% and the Nasdaq Biotech Index has returned
+4.00%.

·     Avidity drove returns for the second quarter in a row. The company
shared Phase 1 data for its second program, FSHD, another muscular dystrophy
with no approved drugs that ends with patients in wheelchairs. Treatment
improved muscle damage markers and increased muscle strength. After some
struggles the past couple years, second generation RNA medicines are now
delivering exciting breakthroughs.

·     The Company completed investments in six new portfolio companies in
the first half of the year, including two in obesity. This included the
Manager's latest company creation, nicknamed Hercules. Hercules is one of the
largest biotech company creations this year. Its clinical stage pipeline
includes an injectable GLP-GIP and an oral GLP in-licensed from Hengrui, one
of China's leading biopharma companies. The other was BioAge Labs. The Company
participated in BioAge's Series D financing round in which they raise $170m to
support Phase 2 clinical development of its lead compound, Azelaprag, an oral
drug with the potential to significantly increase weight loss and improve body
composition (i.e. prevent muscle atrophy) when combined with any incretin
(i.e. GLP-1s and GIPs).

·      Private holding, Numab Therapeutics, a next generation immunology
and immune-oncology company, announced that Johnson & Johnson will acquire
Yellow Jersey Therapeutics, its wholly owned subsidiary, for $1.25bn.

 

 

For Further Information

 RTW Investments, LP                                      +44 20 7959 6361
 Woody Stileman, Managing Director, Business Development  biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune, Director, Investor Relations

 Buchanan (PR & Communications Adviser)                   +44 20 7466 5107
 Charles Ryland
 Henry Wilson
 George Beale

 Deutsche Numis (Joint Corporate Broker)                  +44 20 7260 1000
 Freddie Barnfield
 Nathan Brown
 Euan Brown

 BofA Securities (Joint Corporate Broker)                 +44 20 7628 1000
 Edward Peel
 Alex Penney

 Cadarn Capital (Distribution & IR Partner)               +44 73 6888 3211
 David Harris

 Elysium Fund Management Limited                          +44 14 8181 0100

 Joanna Duquemin Nicolle, Chief Executive Officer

 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC                     +1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund
focused on identifying transformative assets with high growth potential across
the biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFLTDEISLIS